Yujing Di, Ling Yang, Jianfei Zhou, Libo Zhang, Yanqiu Huang, Yingmin Jia, Hongyue Yan, Li Chen, Qiaoyun Hou, Bo Chen, Zhu Luo, Jie Hou
{"title":"CM326在健康成人中从临床前研究到随机I期临床试验的转化研究","authors":"Yujing Di, Ling Yang, Jianfei Zhou, Libo Zhang, Yanqiu Huang, Yingmin Jia, Hongyue Yan, Li Chen, Qiaoyun Hou, Bo Chen, Zhu Luo, Jie Hou","doi":"10.1007/s40259-025-00714-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thymic stromal lymphopoietin (TSLP) plays a pivotal role in immune responses. CM326 is a humanized monoclonal antibody targeting TSLP.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the preclinical characterization, safety, tolerability, pharmacokinetics, and immunogenicity of CM326 in healthy adults.</p><p><strong>Methods: </strong>In vitro pharmacologic activity of CM326 was compared with that of tezepelumab. In vivo efficacy of CM326 was assessed in allergic cynomolgus monkeys. Subjects in single ascending dose trials were randomized 2:1 (22 mg), 4:1 (55/110/220/440/660/880 mg), and 3:1 (330 mg) to receive CM326 or placebo subcutaneously. Subjects in multiple ascending dose trials were randomized 4:1 (55/110/220 mg every 2 weeks [Q2W], 220 mg Q4W) and 3:1 (440 mg Q2W) to receive CM326 or placebo.</p><p><strong>Results: </strong>CM326 revealed higher potency over tezepelumab in blocking T<sub>h</sub>2-driven inflammation in vitro and ameliorated lung function and normalized the inflammatory microenvironment in vivo. CM326 was well tolerated with no discernible safety signals. CM326 showed linear pharmacokinetics over the dose range 22-880 mg. Mean accumulation ratio of AUC was 4.04, 3.87, and 3.74 for 55 mg, 110 mg, and 220 mg Q2W after six doses and 2.16 for 440 mg Q2W after three doses. The mean accumulation ratio of maximum concentration (C<sub>max</sub>) was 3.66 and 1.52 for 220 mg Q2W and Q4W, respectively. Anti-drug antibodies (ADAs) were positive in 2/58 subjects after a single dose of CM326, 2/12 receiving placebo and 3/44 receiving CM326 after multiple doses.</p><p><strong>Conclusions: </strong>CM326 improved T<sub>h</sub>2 inflammation preclinically and demonstrated an acceptable safety profile with linear pharmacokinetics and low immunogenicity in healthy adults.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov identifiers: NCT04842201 (registered on 8 April 2021), NCT05171348 (registered on 9 December 2021), NCT05715333 (registered on 27 January 2023).</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults.\",\"authors\":\"Yujing Di, Ling Yang, Jianfei Zhou, Libo Zhang, Yanqiu Huang, Yingmin Jia, Hongyue Yan, Li Chen, Qiaoyun Hou, Bo Chen, Zhu Luo, Jie Hou\",\"doi\":\"10.1007/s40259-025-00714-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Thymic stromal lymphopoietin (TSLP) plays a pivotal role in immune responses. CM326 is a humanized monoclonal antibody targeting TSLP.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the preclinical characterization, safety, tolerability, pharmacokinetics, and immunogenicity of CM326 in healthy adults.</p><p><strong>Methods: </strong>In vitro pharmacologic activity of CM326 was compared with that of tezepelumab. In vivo efficacy of CM326 was assessed in allergic cynomolgus monkeys. Subjects in single ascending dose trials were randomized 2:1 (22 mg), 4:1 (55/110/220/440/660/880 mg), and 3:1 (330 mg) to receive CM326 or placebo subcutaneously. Subjects in multiple ascending dose trials were randomized 4:1 (55/110/220 mg every 2 weeks [Q2W], 220 mg Q4W) and 3:1 (440 mg Q2W) to receive CM326 or placebo.</p><p><strong>Results: </strong>CM326 revealed higher potency over tezepelumab in blocking T<sub>h</sub>2-driven inflammation in vitro and ameliorated lung function and normalized the inflammatory microenvironment in vivo. CM326 was well tolerated with no discernible safety signals. CM326 showed linear pharmacokinetics over the dose range 22-880 mg. Mean accumulation ratio of AUC was 4.04, 3.87, and 3.74 for 55 mg, 110 mg, and 220 mg Q2W after six doses and 2.16 for 440 mg Q2W after three doses. The mean accumulation ratio of maximum concentration (C<sub>max</sub>) was 3.66 and 1.52 for 220 mg Q2W and Q4W, respectively. Anti-drug antibodies (ADAs) were positive in 2/58 subjects after a single dose of CM326, 2/12 receiving placebo and 3/44 receiving CM326 after multiple doses.</p><p><strong>Conclusions: </strong>CM326 improved T<sub>h</sub>2 inflammation preclinically and demonstrated an acceptable safety profile with linear pharmacokinetics and low immunogenicity in healthy adults.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov identifiers: NCT04842201 (registered on 8 April 2021), NCT05171348 (registered on 9 December 2021), NCT05715333 (registered on 27 January 2023).</p>\",\"PeriodicalId\":9022,\"journal\":{\"name\":\"BioDrugs\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BioDrugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40259-025-00714-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioDrugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40259-025-00714-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults.
Background: Thymic stromal lymphopoietin (TSLP) plays a pivotal role in immune responses. CM326 is a humanized monoclonal antibody targeting TSLP.
Objective: The aim of this study was to evaluate the preclinical characterization, safety, tolerability, pharmacokinetics, and immunogenicity of CM326 in healthy adults.
Methods: In vitro pharmacologic activity of CM326 was compared with that of tezepelumab. In vivo efficacy of CM326 was assessed in allergic cynomolgus monkeys. Subjects in single ascending dose trials were randomized 2:1 (22 mg), 4:1 (55/110/220/440/660/880 mg), and 3:1 (330 mg) to receive CM326 or placebo subcutaneously. Subjects in multiple ascending dose trials were randomized 4:1 (55/110/220 mg every 2 weeks [Q2W], 220 mg Q4W) and 3:1 (440 mg Q2W) to receive CM326 or placebo.
Results: CM326 revealed higher potency over tezepelumab in blocking Th2-driven inflammation in vitro and ameliorated lung function and normalized the inflammatory microenvironment in vivo. CM326 was well tolerated with no discernible safety signals. CM326 showed linear pharmacokinetics over the dose range 22-880 mg. Mean accumulation ratio of AUC was 4.04, 3.87, and 3.74 for 55 mg, 110 mg, and 220 mg Q2W after six doses and 2.16 for 440 mg Q2W after three doses. The mean accumulation ratio of maximum concentration (Cmax) was 3.66 and 1.52 for 220 mg Q2W and Q4W, respectively. Anti-drug antibodies (ADAs) were positive in 2/58 subjects after a single dose of CM326, 2/12 receiving placebo and 3/44 receiving CM326 after multiple doses.
Conclusions: CM326 improved Th2 inflammation preclinically and demonstrated an acceptable safety profile with linear pharmacokinetics and low immunogenicity in healthy adults.
Clinical trial registration: ClinicalTrials.gov identifiers: NCT04842201 (registered on 8 April 2021), NCT05171348 (registered on 9 December 2021), NCT05715333 (registered on 27 January 2023).
期刊介绍：
An essential resource for R&D professionals and clinicians with an interest in biologic therapies.
BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.
BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
